Evaluation of safety and efficacy of Protopic for vitiliginous patients

An open, self-control and multiple-center study to evaluate safety and efficacy of Protopic (0.1% tacrolimus) for vitiliginous patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-10000797

Enrollment

Unknown

Registered

2010-03-15

Start date

2010-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

Group A:Administration of 0.1%Tacrolimus

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with vitiliginous lesions on face/ neck (Examination with Wood's light); 2. Stable vitiligo; 3. With informed consent form signed.

Exclusion criteria

Exclusion criteria: 1. Acral and scattered vitiligo, automatic re-color tendency; 2. Koebner history; 3. Light treatment in 4 weeks; 4. Local therapy by using hormone, immunoregulant (eg. Pimecrolimus), and VitD derivant (eg. Daivonex); 5. Taken medicine such as methopterin, etretinate and ciclosporine in 2 weeks; 6. Skin transplantation failure; 7. Taking photosensitive drug; 8. Other skin diseases which might affect efficacy observation caused by infection, tumor and auto-immune disease; 9. Known allergy to Tacrolimus or ingredients in Tacrolimus ointment; 10. Pregnancy or breasting.

Design outcomes

Primary

Measure	Time frame
Level of pigment restoration;Area of pigment restoration;	—

Countries

China

Contacts

Public ContactXuejun Zhu

zhuxj@public.bta.net.cn+86 010 66551122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026